English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

• The findings of this study indicate that in patients with PN, NAL-ER tablets, at a dose of 162 mg b.i.d., appear to have a measurable antipruritic effect for patients who successfully maintain the initial therapy for at least 10 weeks. • The significantly greater response rate for NAL-ER 162 mg patients who completed the full 10 weeks of double-blind treatment compared with placebo is consistent with a clinical benefit that requires compliance with the designated dosing schedule and duration. • Further evaluation of NAL-ER, including further elucidation of its underlying mechanism of action, is thus warranted in this difficult-to-treat disease, with a larger phase 2b/3 clinical trial currently evaluating the 162 mg b.i.d. dose. Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open-Label Extension Phase Elke Weisshaar1; Thomas R. Sciascia2; Sonja Ständer3 1Occupational Dermatology, Department of Dermatology, University Hospital, Heidelberg, Germany; 2Trevi Therapeutics, New Haven, CT, USA; 3Department of Dermatology and Center for Chronic Pruritus, University Hospital, Münster, Germany

skin

Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase